A double-blind, placebo-controlled comparative study and open-label extension study to confirm the efficacy and safety of E2020 in subjects with down syndrome having regression symptoms and disabled activities of daily living

Trial Profile

A double-blind, placebo-controlled comparative study and open-label extension study to confirm the efficacy and safety of E2020 in subjects with down syndrome having regression symptoms and disabled activities of daily living

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 May 2016

At a glance

  • Drugs Donepezil (Primary)
  • Indications Down syndrome
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 10 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top